FDA drug shortage list and peptide compounding: how to verify a clinic’s claim

01

Start with FDA’s national definition, not a local stock message

FDA considers a drug to be in shortage when nationwide demand or projected demand exceeds supply. A pharmacy that cannot fill an order, a wholesaler delay, a clinic waitlist, or a manufacturer allocation may reflect a real access problem without establishing that the drug appears on FDA’s statutory shortage list.

The distinction matters because federal compounding provisions refer to FDA’s list, not to an advertisement saying limited supply. FDA’s public database includes current shortages, resolved shortages, discontinuations, reasons, manufacturers, presentations, and availability information. Most supply information comes from manufacturers and can change.

Search by generic or active-ingredient name, then match the dosage form and presentation. Brand-only searching can miss a record or create a false match. Save the result, URL, date, status, and the exact product details rather than writing only shortage confirmed.

02

What shortage status can change under section 503A

Section 503A restricts regular or inordinate compounding of products that are essentially copies of commercially available drugs. FDA explains that a drug on its shortage list is not considered commercially available for that analysis, so the specific copying limitation does not apply in the same way during the shortage.

Other 503A conditions remain. FDA specifically notes the requirement for a valid prescription for an identified individual patient. Ingredient eligibility, state licensure, applicable pharmacy standards, product labeling, and the clinical reason for the prescription do not disappear because a national shortage exists.

A provider should not translate shortage into any pharmacy may make any version. The product, active ingredient, route, patient prescription, compounder, date, and remaining legal conditions still need support. A compounded product also remains unapproved and does not acquire the approved product’s label or evidence.

03

What shortage status can change under section 503B

Outsourcing facilities are restricted from making products that are essentially copies of FDA-approved drugs. FDA explains that the identical-or-nearly-identical limitation does not apply in the same way when the approved drug is on the shortage list at the time relevant to compounding, distribution, and dispensing.

Shortage status can also matter to bulk-substance eligibility. FDA’s comparison of sections 503A and 503B states that a 503B bulk substance generally must appear on the 503B Bulks List or be used to compound a drug that appears on FDA’s shortage list at the time of compounding, distribution, and dispensing.

That rule is not a facility quality rating or product approval. The outsourcing facility still must satisfy applicable CGMP, registration, product reporting, labeling, adverse-event reporting, and other conditions. A 503B label describes a federal framework, not an FDA guarantee.

04

Resolution can change the answer quickly

FDA updates the shortage list daily with new and resolved shortages. Its FAQ distinguishes the agency’s resolved determination from a manufacturer presentation marked available. A presentation may be reported available while the nationwide shortage remains, and a local pharmacy may still lack stock after FDA resolves the national shortage.

For 503B facilities, FDA describes limited enforcement flexibility for orders received while the drug was in shortage. The agency says it may act if a facility fills new orders after removal or continues filling existing orders more than 60 days after removal. The timeline is not a permanent grace period for a clinic’s future sales.

Date every claim at multiple points: when the pharmacy compounded the drug, when it distributed it, when it was dispensed, and when the clinic advertised it. A single old screenshot cannot prove all four. Ask the responsible pharmacy to explain the current basis rather than expecting a consumer to infer compliance.

05

Shortage does not prove equivalence, quality, or appropriateness

FDA says compounded drugs pose higher risk than approved drugs because they do not undergo premarket review for safety, effectiveness, or quality. A shortage-related pathway can address access; it does not show that a compounded vial is therapeutically equivalent, an approved generic, or manufactured under the approved sponsor’s controls.

Differences may involve concentration, container, delivery device, excipients, instructions, testing, stability, and dosing presentation. A clinic that says same drug should identify which characteristics are the same and which differ. Consumers should not use that comparison to calculate or change a dose.

Availability and medical need are separate. FDA recommends approved drugs when available and appropriate, while recognizing that compounded drugs may meet needs in some circumstances. An appropriately licensed clinician and pharmacist must evaluate the individual situation; a directory cannot select an alternative.

06

A dated workflow for checking a clinic’s shortage claim

Capture the clinic’s statement, date, exact drug, active ingredient, route, and claimed pharmacy pathway. Search FDA’s database and open the product record. Confirm current versus resolved status and match the presentation rather than relying on a search snippet or news article.

Identify whether the compounder is a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility. Verify the legal name and address. Then ask which shortage-related provision the pharmacy relies on, what dates apply, and what other conditions it has documented.

Finally, check the label, pharmacy license, FDA inspection and recall records where applicable, and the provider’s explanation of differences from the approved product. Recheck immediately before relying on the result because the list can change daily.

• →Exact active ingredient and presentation
• →FDA shortage status and date
• →503A or 503B pathway
• →Compounding, distribution, and dispensing dates
• →Compounder name, address, and records
• →Approved-versus-compounded product differences